Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
/ 100 items
#LLY↓
Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
JPMorgan Initiates Overweight on Tango Therapeutics with $46 Target as Pancreatic Cancer Data Impresses
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
JPMorgan Raises Eli Lilly Price Target to $1,400 on Mounjaro’s Obesity and Pediatric Momentum
Health Canada has approved Mounjaro for children with type 2 diabetes.